{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T23:11:20Z","timestamp":1792710680260,"version":"4.5.0"},"reference-count":36,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020992","name":"Caisse nationale de l'Assurance Maladie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020992","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes &amp; Metabolism"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.diabet.2025.101638","type":"journal-article","created":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T11:35:08Z","timestamp":1742124908000},"page":"101638","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Persistent gaps in the implementation of lipid-lowering therapy in patients with established atherosclerotic cardiovascular disease: A French nationwide study"],"prefix":"10.1016","volume":"51","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6027-9486","authenticated-orcid":false,"given":"Matthieu","family":"Wargny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Goronflot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Guillaume","family":"Piriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Pouriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Bastien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Prax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Leux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9ry-Pierre","family":"Riche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-No\u00ebl","family":"Trochu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"B\u00e9liard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nad\u00e8ge","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Ferri\u00e8res","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phanie","family":"Duret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Cariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diabet.2025.101638_bib0001","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","article-title":"Global burden of cardiovascular diseases and risk factors, 1990\u20132019","volume":"76","author":"Roth","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.diabet.2025.101638_bib0002","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1093\/eurheartj\/ehx144","article-title":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel","volume":"38","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2025.101638_bib0003","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/S0140-6736(04)17018-9","article-title":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study","volume":"364","author":"Yusuf","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2025.101638_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.891929","article-title":"The Global Burden of Diseases attributed to high low-density lipoprotein cholesterol from 1990 to 2019","volume":"10","author":"Zheng","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.diabet.2025.101638_bib0005","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2458-9-33","article-title":"Ecological association between a deprivation index and mortality in France over the period 1997 - 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death","volume":"9","author":"Rey","year":"2009","journal-title":"BMC Public Health"},{"key":"10.1016\/j.diabet.2025.101638_bib0006","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.cell.2015.01.036","article-title":"A century of cholesterol and coronaries: from plaques to genes to statins","volume":"161","author":"Goldstein","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.diabet.2025.101638_bib0007","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101638_bib0008","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101638_bib0009","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101638_bib0010","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJMoa2215024","article-title":"Bempedoic acid and cardiovascular outcomes in statin-intolerant patients","volume":"388","author":"Nissen","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101638_bib0011","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2025.101638_bib0012","article-title":"Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study","volume":"29","author":"Ray","year":"2023","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.diabet.2025.101638_bib0013","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"Suppl4","key":"10.1016\/j.diabet.2025.101638_bib0014","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d'information interr\u00e9gimes de l'Assurance Maladie (SNIIRAM) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (SNDS) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"10.1016\/j.diabet.2025.101638_bib0015","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/CIRCOUTCOMES.122.009787","article-title":"Gaps in guideline-based lipid-lowering therapy for secondary prevention in the United States: a retrospective cohort study of 322,153 Patients","volume":"16","author":"Navar","year":"2023","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.diabet.2025.101638_bib0016","doi-asserted-by":"crossref","first-page":"e23445","DOI":"10.1097\/MD.0000000000023445","article-title":"Prevalence and management of hypercholesterolemia in France, the Esteban observational study","volume":"99","author":"Blacher","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.diabet.2025.101638_bib0017","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijcard.2021.03.007","article-title":"Clinical impact and room for improvement of intensity and adherence to lipid lowering therapy: five years of clinical follow-up from 164,565 post-myocardial infarction patients","volume":"332","author":"Schiele","year":"2021","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.diabet.2025.101638_bib0018","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2019.03.014","article-title":"Management of dyslipidaemia in patients with coronary heart disease: results from the ESC-EORP EUROASPIRE V survey in 27 countries","volume":"285","author":"De Backer","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabet.2025.101638_bib0019","first-page":"zwae199","article-title":"Use of combination therapy is associated with improved LDL-cholesterol management: 1-year follow-up results from the European observational SANTORINI study","author":"Ray","year":"2024","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.diabet.2025.101638_bib0020","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","article-title":"EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study","volume":"28","author":"Ray","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.diabet.2025.101638_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2024.131775","article-title":"The impact of early in-hospital use of PCSK9 inhibitors on cardiovascular outcomes in acute coronary syndrome patients: a systematic review and meta-analysis","volume":"399","author":"Yifan","year":"2024","journal-title":"International J Cardiol"},{"key":"10.1016\/j.diabet.2025.101638_bib0022","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1093\/cvr\/cvae109","article-title":"Inclisiran administration potently and durably lowers LDL-C over an extended-term follow-up: the ORION-8 trial","volume":"120","author":"Wright","year":"2024","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.diabet.2025.101638_bib0023","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.diabet.2025.101638_bib0024","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.atherosclerosis.2017.12.031","article-title":"The challenge of peripheral arterial disease: how do we improve outcome?","volume":"270","author":"Stock","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.diabet.2025.101638_bib0025","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1910355","article-title":"A comparison of two LDL cholesterol targets after ischemic stroke","volume":"382","author":"Amarenco","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabet.2025.101638_bib0026","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1016\/S0140-6736(21)00684-X","article-title":"The Lancet women and cardiovascular disease Commission: reducing the global burden by 2030","volume":"397","author":"Vogel","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2025.101638_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104514","article-title":"Sex-differences in factors and outcomes associated with adherence to statin therapy in primary care: need for customisation strategies","volume":"155","author":"Olmastroni","year":"2020","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.diabet.2025.101638_bib0028","first-page":"ehae558","article-title":"Variation in secondary prevention of coronary heart disease: the INTERASPIRE Study","author":"McEvoy","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2025.101638_bib0029","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(18)31942-1","article-title":"Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials","volume":"393","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2025.101638_bib0030","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCOUTCOMES.123.010685","article-title":"Association of use and dose of lipid-lowering therapy post acute myocardial infarction with 5-year survival in older adults","volume":"17","author":"Fayol","year":"2024","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.diabet.2025.101638_bib0031","doi-asserted-by":"crossref","first-page":"3516","DOI":"10.1093\/eurheartj\/ehz458","article-title":"Cardiovascular effect of discontinuing statins for primary prevention at the age of 75 years: a nationwide population-based cohort study in France","volume":"40","author":"Giral","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.diabet.2025.101638_bib0032","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1016\/S0140-6736(21)01122-3","article-title":"Global perspective of familial hypercholesterolaemia: a cross-sectional study from the EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC)","volume":"398","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.diabet.2025.101638_bib0033","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1161\/CIRCRESAHA.121.319811","article-title":"Social Determinants of Cardiovascular Disease","volume":"130","author":"Powell-Wiley","year":"2022","journal-title":"Circ Res"},{"key":"10.1016\/j.diabet.2025.101638_bib0034","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jacl.2022.12.003","article-title":"Impact of telehealth on the current and future practice of lipidology: a scoping review","volume":"17","author":"Schubert","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.diabet.2025.101638_bib0035","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.tcm.2023.08.001","article-title":"Practical solutions for implementation of blood cholesterol guidelines in clinical practice","volume":"34","author":"Piazza","year":"2024","journal-title":"Trends Cardiovasc Med"},{"key":"10.1016\/j.diabet.2025.101638_bib0036","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1093\/eurjpc\/zwac161","article-title":"Temporal trends in atherosclerotic cardiovascular disease risk among U.S. adults. Analysis of the National Health and Nutrition Examination Survey, 1999-2018","volume":"29","author":"Chobufo","year":"2022","journal-title":"Eur J Prev Cardiol"}],"container-title":["Diabetes &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1262363625000333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T22:15:04Z","timestamp":1772230504000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1262363625000333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1262363625000333"],"URL":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101638","relation":{},"ISSN":["1262-3636"],"issn-type":[{"value":"1262-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent gaps in the implementation of lipid-lowering therapy in patients with established atherosclerotic cardiovascular disease: A French nationwide study","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabet.2025.101638","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"101638"}}